Aurinia Pharmaceuticals Inc. (AUPH) Market Cap & Valuation Ratios
Aurinia Pharmaceuticals Inc. (AUPH) has a market cap of $2.2B and a price-to-sales ratio of 7.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AUPHAurinia Pharmaceuticals Inc.Follow AUPH — free
—
Price chart with a free account
- Market cap
- 2.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| AUPH | 2.2 | — | 5.8 | 10.6 | 7.8% | +20% | 48% | 33% |
| ADMA | 2.4 | 15.3 | 4.8 | 10.6 | 4.9% | +8% | 44% | 37% |
| RCUS | 2.4 | — | 15.0 | — | — | -55% | -415% | -120% |
| MBX | 2.3 | — | — | — | -3.6% | — | — | -44% |
| SLS | 2.3 | — | — | — | — | — | — | — |
| CLDX | 2.3 | — | — | — | -10.5% | -97% | — | -50% |
| FTRE | 2.2 | — | 1.2 | 46.4 | 8.7% | -2% | -0.4% | -0.7% |
| PGEN | 2.2 | — | 26.5 | — | -5.2% | +147% | -46% | -33% |
| AGIO | 2.2 | — | 16.2 | — | — | +141% | -467% | -41% |
| VCEL | 2.2 | 90.5 | 6.6 | 64.7 | 2.8% | +23% | 6% | 7% |
| HRMY | 2.1 | 11.7 | 1.7 | 6.2 | 16.9% | +24% | 24% | 35% |
| Median of these 10 | 15.3 | 6.6 | 28.5 | 2.8% | +15% | -0.4% | -33% |
; EV/Sales 5.8 vs. 6.6.
Growth vs. price
each dot a company · hover or tap for valuesAUPH and RCUS and MBX and SLS and CLDX and FTRE and PGEN and AGIO have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Aurinia Pharmaceuticals Inc. — questions
- What is Aurinia Pharmaceuticals Inc.'s market cap?
- $2.2B.
- What is Aurinia Pharmaceuticals Inc.'s price-to-sales ratio?
- 7.2.
Every figure on this page comes from Aurinia Pharmaceuticals Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.